Mezavant

Mesalazine, the active ingredient in Mezavant, is a aminosalicylate presented as a delayed‑release tablet for oral use. It treats ulcerative colitis and is used in adult patients to manage inflammation of the colon.

GNH USA supplies Mezavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mezavant (mesalazine) is an aminosalicylate used to treat inflammatory conditions of the colon.

Ulcerative colitis (induction): reduces active inflammation and promotes symptom relief. Ulcerative colitis (maintenance): helps sustain remission and prevent relapse. Ulcerative proctitis: controls inflammation limited to the rectum.

Adverse reactions may occur with Mezavant use.

Common Side Effects: - Headache - Nausea - Abdominal pain - Flatulence

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatotoxicity, including elevated liver enzymes - Acute pancreatitis - Blood dyscrasias such as neutropenia or agranulocytosis

Use Mezavant with appropriate clinical monitoring.

Monitor renal function: assess creatinine and eGFR before and during therapy. Monitor hepatic function: check liver enzymes periodically. Assess disease activity: ensure appropriate indication before initiation. Avoid in patients with known hypersensitivity to salicylates. Use with caution in severe ulcerative colitis or extensive disease. Store at ambient temperature: keep in the original pack, protect from moisture.

Mesalazine may interact with several medicines.

Major Interactions (Avoid): - Warfarin: increased risk of bleeding. - Methotrexate: heightened toxicity risk. - Azathioprine: potential for bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate gastrointestinal irritation. - Oral corticosteroids: may affect disease control and increase infection risk. - Live vaccines: possible reduced efficacy, consider timing of administration.